Pediatrics：接种疫苗不会导致自闭症
新的研究发现，暴露于最高水平硫柳汞（充满水银的防腐剂，其常见于许多疫苗中）的婴儿不比仅接触很少硫柳汞的婴儿更可能罹患自闭症。
该研究为那些担心孩子接种疫苗增加自闭症风险的父母提供了更大的安全感，研究人员说。
“产前和生命早期接触疫苗或免疫球蛋白制品中的硫柳汞不会增加孩子罹患自闭症的风险，”高级研究作者、美国疾病控制与预防中心免疫安全办公室主任Frank DeStefano博士总结道。
这项研究9月13日在线发表，早于10月份印刷版《Pediatrics》。
据文章的背景资料，硫柳汞自20世纪30年代起被用作疫苗防腐剂。
在这项新研究中，研究人员检查了医疗记录且对256名自闭症谱系障碍儿童及与其出生年份相匹配的752名未患自闭症儿童进行了面谈。这些儿童均是加利福尼亚州和马萨诸塞州的的3个保健护理管理机构的成员。
研究人员还收集了很多有关产品和儿童所接种的许多疫苗的信息，以确定儿童可能接触到多少硫柳汞。
对于最高的10%硫柳汞暴露组儿童，无论是产前或婴儿期与20个月之间，罹患自闭症、自闭症谱系障碍或者退行性自闭症谱系障碍的可能性不比最少的10%硫柳汞暴露组儿童的小。
“这项研究提示，早期经接种疫苗接触硫柳汞不会引致自闭症，”一家领先的国家宣传机构——自闭症如是说的首席科学官Geraldine Dawson说。Dawson没有参与这项研究。（生物谷Bioon.com）
生物谷推荐原文出处：
Pediatrics doi:10.1542/peds.2010-0309
Prenatal and Infant Exposure to Thimerosal From Vaccines and Immunoglobulins and Risk of Autism
Cristofer S. Price, ScM,a William W. Thompson,PhD,b Barbara Goodson, PhD,a Eric S. Weintraub, MPH,cLisa A. Croen, PhD,d Virginia L. Hinrichsen, MS, MPH,eMichael Marcy, MD,f Anne Robertson, PhD,a Eileen Eriksen, MPH,f Edwin Lewis, MPH,d Pilar Bernal, MD,gDavid Shay, MD, MPH,h Robert L. Davis, MD, MPH,i and Frank DeStefano, MD, MPHc
OBJECTIVE: Exposure to thimerosal, a mercury-containing preservative that is used in vaccines and immunoglobulin preparations, has been hypothesized to be associated with increased risk of autism spectrum disorder (ASD). This study was designed to examine relationships between prenatal and infant ethylmercury exposure from thimerosalcontaining vaccines and/or immunoglobulin preparations and ASD and 2 ASD subcategories: autistic disorder (AD) and ASD with regression.
METHODS: A case-control study was conducted in 3 managed care organizations (MCOs) of 256 children with ASD and 752 controls matched by birth year, gender, and MCO. ASD diagnoses were validated through standardized in-person evaluations. Exposure to thimerosal in vaccines and immunoglobulin preparations was determined from electronic immunization registries, medical charts, and parent interviews.
Information on potential confounding factors was obtained from the interviews and medical charts. We used conditional logistic regression to assess associations between ASD, AD, and ASD with regression and exposure to ethylmercury during prenatal, birth-to-1 month, birthto-7-month, and birth-to-20-month periods.
RESULTS: There were no findings of increased risk for any of the 3 ASD outcomes. The adjusted odds ratios (95% confidence intervals) for ASD associated with a 2-SD increase in ethylmercury exposure were 1.12 (0.83–1.51) for prenatal exposure, 0.88 (0.62–1.26) for exposure from birth to 1 month, 0.60 (0.36–0.99) for exposure from birth to 7 months, and 0.60 (0.32– 0.97) for exposure from birth to 20 months.
CONCLUSIONS: In our study of MCO members, prenatal and early-life exposure to ethylmercury from thimerosal-containing vaccines and immunoglobulin preparations was not related to increased risk of ASDs
